NAD+ metabolism and therapeutic strategies in cardiovascular diseases

• Published in: Atherosclerosis plus 2024-09, Vol.57, p.1-12
• Main Authors: Shi, Chongxu, Wen, Zhaozhi, Yang, Yihang, Shi, Linsheng, Liu, Dong
• Format: Article
• Language: English
• Subjects: Atherosclerosis; Cardiovascular diseases; Nicotinamide adenine dinucleotide; Review; Vascular disorder
• ISSN: 2667-0895; 2667-0909; 2667-0895
• DOI: 10.1016/j.athplu.2024.06.001

Nicotinamide adenine dinucleotide (NAD+) is a central and pleiotropic metabolite involved in cellular energy metabolism, cell signaling, DNA repair, and protein modifications. Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Metabolic stress and aging directly affect the cardiovascular system. Compelling data suggest that NAD + levels decrease with age, obesity, and hypertension, which are all notable risk factors for CVD. In addition, the therapeutic elevation of NAD + levels reduces chronic low-grade inflammation, reactivates autophagy and mitochondrial biogenesis, and enhances oxidative metabolism in vascular cells of humans and rodents with vascular disorders. In preclinical models, NAD + boosting can also expand the health span, prevent metabolic syndrome, and decrease blood pressure. Moreover, NAD + storage by genetic, pharmacological, or natural dietary NAD + -increasing strategies has recently been shown to be effective in improving the pathophysiology of cardiac and vascular health in different animal models, and human health. Here, we review and discuss NAD + -related mechanisms pivotal for vascular health and summarize recent experimental evidence in NAD + research directly related to vascular disease, including atherosclerosis, and coronary artery disease. Finally, we comparatively assess distinct NAD + precursors for their clinical efficacy and the efficiency of NAD + elevation in the treatment of major CVD. These findings may provide ideas for new therapeutic strategies to prevent and treat CVD in the clinic. [Display omitted]